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Abstract Among lean populations, cardiovascular disease
(CVD) is rare. Among those with increased adiposity, CVD is
the commonest cause of worldwide death. The “obesity para-
dox” describes seemingly contrary relationships between body
fat and health/ill-health. Multiple obesity paradoxes exist, and
include the anatomic obesity paradox, physiologic obesity par-
adox, demographic obesity paradox, therapeutic obesity para-
dox, cardiovascular event/procedure obesity paradox, and obe-
sity treatment paradox. Adiposopathy (“sick fat”) is defined as
adipocyte/adipose tissue dysfunction caused by positive caloric
balance and sedentary lifestyle in genetically and environmen-
tally susceptible individuals. Adiposopathy contributes to the
commonest metabolic disorders encountered in clinical practice
(high glucose levels, high blood pressure, dyslipidemia, etc.),
all major CVD risk factors. Ockham's razor is a principle of
parsimonywhich postulates that among competing theories, the
hypothesis with the fewest assumptions is the one best selected.
Ockham’s razor supports adiposopathy as the primary cause of
most cases of adiposity-related metabolic diseases, which in
turn helps resolve the obesity paradox.
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Introduction
Among rural hunter-gatherers, cardiovascular disease (CVD)
is rare [1], and is independent of nutritional quality (i.e.,
amount of dietary fat) [2]. Total energy expenditure among
rural hunter-gatherers does not differ from that among mem-
bers of more industrialized populations [3]. Thus, reduced
nutritional quantity and limited body fat storage best explains
why hunter-gatherers have body mass index (BMI) less than
20 kg/m2 and minimal CVD risk factors [4], including mean
total cholesterol levels of 110–150 mg/dl [5, 6].
Globally, more than one billion adults are overweight
(BMI≥25 kg/m2); at least 300 million are obese (BMI≥
30 kg/m2) [7]. Over two thirds of the US population are
overweight or obese [8], withmean total cholesterol level almost
twice those of hunter-gatherers (i.e., 200 mg/dl or greater) [5, 6].
When BMI increases, so does the incidence of metabolic dis-
eases, many being major CVD risk factors [6]. Hunter-gatherer
populations have low BMI, low prevalence of CVD risk factors,
and a low rate of CVD. More industrialized populations have
higher BMI, higher prevalence of CVD risk factors, and expe-
rience CVD as the single commonest cause of death [9]. The
World Health Organization has characterized obesity and its
metabolic consequences as a global epidemic [7].
This review explores the adiposopathic changes that often
accompany an increased amount of body fat, and why they are
best considered the “primary cause” of metabolic diseases and
increased CVD risk. Understanding adiposopathy better allows
clinicians to explain to patients how an increased amount of
body fat leads to “sick fat” and ill-health. By recognizing the
pathogenic potential of adipocytes and adipose tissue, clinicians
and patients can better resolve the so-called obesity paradox.
Adiposopathy and History
Approximately 400 BC, Hippocrates stated: “It is very injuri-
ous to health to take in more food than the constitution will
bear, when at the same time, one uses no exercise to carry off
this excess. For as aliment fills, and exercise empties the body,
the result of an exact equipoise between themmust be to leave
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the body in the same state they found it, that is, in perfect
health” [10]. In the 1700 s, Morgagni published “The seats
and causes of disease investigated by anatomy,” wherein he
postulated health resulted from a vital harmony of a well-
balanced function of body organs [11]. In the 1920s,
obesity/central obesity was found to cluster with hyperglyce-
mia, hypertension, hyperuricemia, and hyperlipidemia [12]. In
the 1940s, Vague [13] described the association of increased
abdominal obesity and the increased risk of CVD among men.
Thus, at least since 400 BC, positive caloric balance has been
recognized as potentially injurious to health, at least since the
1920s, central adiposity has been known to cluster with met-
abolic disease, and at least since the 1940s, adipose tissue
distribution has been described as relevant to CVD risk.
Overall, basic medical research has consistently supported
adipocyte and adipose tissue anatomic and physiologic de-
rangements as important contributors to metabolic disease
[14••]. Yet as late as the 1980s, not all were convinced that
adipocytes were much more than inert cells. Adipose tissue
was often perceived as a slothful organ that simply stored
body fat. The relationships between an increased amount of
body fat and metabolic diseases were not typically character-
ized as causal ones, but were rather characterized as “associ-
ations.” An increased amount of body fat was not typically
characterized as a contributor to metabolic diseases; rather
metabolic diseases were characterized as comorbidities.
The lack of definitive causal phraseology reflected the
thinking that if an increase in the amount of body fat did
correlate to metabolic disease and increased CVD risk, then
this was either a chance finding, or was due to some inexpli-
cable and mysterious mechanism. It was so mysterious that
the clustering of increased adiposity (especially central/
visceral obesity) withmetabolic diseases and CVD risk factors
was identified by at least 15 different syndromes, including
atherothrombogenic syndrome, beer-belly syndrome, cardio-
vascular metabolic syndrome, chronic CVD-risk-factor-clus-
tering syndrome, deadly quartet (obesity, hyperinsulinemia,
hypertension, and dyslipidemia), disharmonious quartet,
dysmetabolic syndrome, dysmetabolic syndrome X, insulin
resistance syndrome, insulin resistance–dyslipidemia syn-
drome, metabolic cardiovascular syndrome, metabolic syn-
drome, metabolic syndrome X, multiple metabolic syndrome,
plurimetabolic syndrome, and Reaven’s syndrome [15]. Per-
haps the most cryptic moniker was the apparitional “syndrome
X” [16].
In an effort to bring harmony to divergent voices, the term
“metabolic syndrome” sought to define a common clustering
of CVD risk factors, with increased waist circumference as the
only anatomic diagnostic criterion. Yet even here, different
scientific organizations had different diagnostic criteria
(Table 1). In contrast to the National Cholesterol Education
Program, Adult Treatment Panel III [17, 18], the International
Diabetes Federation (IDF) required central obesity as a
metabolic syndrome diagnostic criterion [19]. As such, al-
though both the National Cholesterol Education Program,
Adult Treatment Panel III and the IDF recognized central
obesity as the only anatomic diagnostic criterion, the IDF
more strongly identified the central role of adipose
tissue in the common clustering of CVD risk factors.
Additionally, the IDF included ethnicity-specific values,
reflecting that different degrees of central obesity had
different clinical implications, based on different genetic
predispositions.
Although defining metabolic syndrome did bring some
order, the term “metabolic syndrome” did not reflect a unified,
pathophysiologic process that accounted for the clustering of
metabolic disorders. Metabolic syndrome was not a “disease,”
and thus was not especially conducive to cause-and-effect
logistical discussions with patients. Also, because it was not
a true “disease,” no therapeutic intervention and/or agent
achieved regulatory approval to treat “metabolic syndrome.”
Finally, the metabolic syndrome diagnosis did not appear to be
a better predictor of future metabolic disease than the assess-
ment of its individual components [20]. Given these uncer-
tainties, in 2005, the American Diabetes Association and the
European Association for the Study of Diabetes issued a joint
statement questioning the clinical utility of “metabolic
syndrome” [21].
Concurrently, research continued to support adipose tissue
disease as relevant to a “common soil” hypothesis [6, 22].
Evidence continued to mount “confirming” that the compo-
nents of metabolic syndrome were due to a single pathophys-
iologic process [23]. But what was this process?What was the
disease? The answer was found from decades of basic science.
Researchers described adipocytes and adipose tissue as meta-
bolically active [20, 24]. Dysfunctional energy storage pro-
duced the anatomic findings of adipocyte hypertrophy/
visceral fat accumulation. Adipocyte and adipose tissue
endocrine/immune dysfunctions both directly, and indirectly,
contributed to metabolic disease and increased CVD risk
[14••].
But perhaps the best evidence was found within the
sanctuarial domain of the clinician and patient. Among the
commoner clinical presentations are patients who, after
gaining body fat, develop increased glucose blood levels,
higher blood pressure, and worsening dyslipidemia. Clini-
cians often intuitively deduce these metabolic diseases were
caused by the increase in the amount of body fat. Hence,
clinicians often recommend patients lose weight (fat) via
behavior modification, nutritional interventions, and increased
physical activity. Such assessments and recommendations are
consistent with the scientific evidence that (1) an increase in
the amount of body fat is often pathogenic, and may contrib-
ute to (“cause”) metabolic disease, and (2) patients with over-
weight or obesity often havemetabolic disease parameters that
improve with fat weight loss.
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“Adiposopathy” and “sick fat” are scientific and clinical
terms, respectively, that simultaneously emerged towards bet-
ter aligning the scientific findings of researchers with the
patient care experience of clinicians. These terms recognized
the pathogenic potential of an increased amount of body fat as
a primary contributor to metabolic disease and increased CVD
risk. In 2004, the first peer-review publication of the term
“adiposopathy” was noted in a review article of investigation-
al antiobesity agents, wherein its conclusion stated: “An
emerging concept is that the development of anti-obesity
agents must not only reduce fat mass (adiposity), but must
also correct fat dysfunction (adiposopathy)” [25]. This was
followed by the first publication identifying “sick fat,” entitled
“Adiposopathy: sick fat causes high blood sugar, high blood
pressure, and dyslipidemia” [15]. Since then, consensus arti-
cles and reviews have better defined adiposopathy as it applies
to clinical endocrinology [26], lipidology [27•], diabetes
mellitus [28••, 29], CVD [14••], bariatric surgery [30, 31],
and other inflammatory disorders [32–37].
It is now generally accepted that adipose tissue has no less
pathogenic potential than other body organs, with
adiposopathy being analogous to cardiomyopathy, myopathy,
encephalopathy, ophthalmopathy, retinopathy, enteropathy,
nephropathy, neuropathy, and dermopathy. “Cardiomyopa-
thy” describes a “disease” wherein pathologic enlargement
of heart cells and heart organ results in anatomic/functional
abnormalities leading to adverse clinical consequences. Sim-
ilarly, “adiposopathy” describes a “disease” wherein patho-
genic enlargement of fat cells and fat organ results in
anatomic/functional abnormalities leading to adverse clinical
consequences. But although the pathogenic potential of adi-
pocytes and adipose tissue has gained acceptance, such was
not necessarily the case as late as 2009, when it was stated
[38]:
A Type 2 diabetes mellitus patient who weighs 300
pounds (with an ideal bodyweight of 150 pounds) may
develop diabetes mellitus eye disease, such as disease of
the retina (a thin layer of cells lining much of the orbit).
The adipose tissue in this patient likely weighs over 150
pounds, and represents this patient’s largest organ by
weight. It seems unreasonable to readily accept the
pathogenic potential of a tissue measured in microns
(retinopathy), yet deny the pathogenic potential of an
organ that can be measured in hundreds of pounds, and
that may constitute over half of the patient’s
bodyweight.
Similarly, the lack of universal acceptance of adipose tissue
as an organ worthy of intervention compelled authors to posit
provocative manuscript titles such as: “Adipose tissue as a
therapeutic target in obesity” [39]. Today, national obesity
guidelines and algorithms incorporate the clinical concepts
and scientific principles of adiposopathy and sick fat. The
2013 Clinical Practice Guidelines for Healthy Eating for the
Prevention and Treatment of Metabolic and Endocrine Dis-
eases in Adults notes that primary disturbances in adipose
tissue anatomy and function (“adiposopathy”) are etiologic
in the development of metabolic derangements [40]. A major
stated focus of nutritional counseling for individuals with
overweight or obesity is to correct “adiposopathy.”
Gonzalez-Campoy et al. [40] recommend that nutritional
counseling of individuals with overweight or obesity be aimed
not only at decreasing fat mass, but also at correcting adipose
tissue dysfunction (“adiposopathy”). The 2013 American As-
sociation of Bariatric Physicians Obesity Algorithm [41••]
(Fig. 1) highlighted how the evaluation of patients with over-
weight or obesity should focus on the presence of “sick fat
disease” (adiposopathy) or “fat mass disease.”
Adiposopathy and Ockham’s Razor
The 2005 review article entitled “Adiposopathy, metabolic
syndrome, quantum physics, general relativity, chaos and the
theory of everything” [42] reviewed how physicists had long
struggled to develop a unifying “theory of everything,” in an
effort to help reconcile understandings of microsystems (via
Table 1 Metabolic syndrome definitions
Updated National Education Cholesterol Education Program, Adult
Treatment Panel III diagnostic criteria for metabolic syndrome include
the presence of 3 of 5 of the following [18]:
1. Elevated waist circumference [men greater than 40 in. (102 cm); women
greater than 35 in. (88 cm)]
2. Elevated level of triglycerides equal to or greater than 150 mg/dL
(1.7 mmol/L)
3. Reduced high-density lipoprotein cholesterol level [men less than
40 mg/dL (1.03 mmol/L); women less than 50 mg/dL (1.29 mmol/L)]
4, Elevated blood pressure (equal to or greater than 130/85 mmHg or use of
medication for hypertension)
5. Elevated fasting glucose level equal to or greater than 100 mg/dL
(5.6 mmol/L) or use of medication for hyperglycemia
The International Diabetes Federation defined metabolic syndrome as the
presence of central obesity with ethnicity-specific values, and any 2 of
the following [19]:
1. Raised level of triglycerides greater than 150 mg/dL (1.7 mmol/L) or
specific treatment for this lipid abnormality,
2. Reduced high-density lipoprotein cholesterol level less than 40 mg/dL
(1.03 mmol/L) in males and less than 50 mg/dL (1.29 mmol/L) in
females or specific treatment for this lipid abnormality
3. Raised blood pressure (i.e., systolic blood pressure greater than
130 mmHg or diastolic blood pressure greater than 85 mmHg or
treatment of previously diagnosed hypertension
4. Raised fasting plasma glucose level greater than 100 mg/dL
(5.6 mmol/L) or previously diagnosed type 2 diabetes
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quantum physics involving molecules, atoms, and subatomic
particles such as electrons and quarks) and macrosystems
(through relativity theories applied to stars galaxies and the
universe itself):
Thus, the challenge has been to find a simple equation
that might unify the macro with the micro and bridge the
gap between the classical relativity concepts and the
quantum concepts of gravity/spacetime. Physicists
strive towards unifying the associations between the
four fundamental forces of the universe: strong forces,
electromagnetic forces, weak forces and gravitational
forces. This has led to superunified theories, or Theories
of Everything, such as superstrings which are mathe-
matically derived, hypothetical units that form the ele-
mentary particles of spacetime (and require the presence
of multiple dimensions). In medicine, we are still grap-
pling with the unification of the pathogenesis of the four
fundamental metabolic diseases of obesity, T2DM, hy-
pertension and dyslipidemia – and we have had our own
conflicts [42].
Among the basic laws of physics applicable to individuals
who are overweight or obese are the concept of chaos or
uncertainty in quantum physics, which allows escape from
the unyielding shackles of predetermination. Chaos allows for
change via free will, which in the case of patients with over-
weight or obesity often includes lifestyle changes. Even the
relativity formula E=mc2 has clinical application:
Some obese patients believe that their metabolic fate is
unavoidable, irrespective of intervention, and come to
develop the defeatist belief that they will always gain fat
mass, even if they reduce consumption of calories/
energy. As previously described, physics dictates that
in order for energy (calories) to decrease while mass
continues to increase would necessitate that the speed of
light decrease respective to the obese patient. This is not
only impossible from a general relativity, spacetime
standpoint, but is seemingly ridiculous, except to the
frustrated obese patient. Thus, a major challenge to
clinicians will be to dispel the notion of inevitability
and instead, emphasize that free-will-based lifestyle in-
terventions can be, and are effective [42].
Table 2 lists anatomic, pathophysiologic, and clinical man-
ifestations of adiposopathy, manifested by disharmonious in-
terplay of micro (cellular) and macro (organ) biological sys-
tems causing/contributing to metabolic disease and increased
CVD risk. However, other contributing mechanisms poten-
tially exist. Pathogenic infestations, via viral infections [43] or
intestinal signaling from gut microbiota [44], are suggested to
potentially increase the amount of body fat and cause adipose
tissue dysfunction. However, little evidence supports
microorganism-mediated mechanisms as superseding the fun-
damental importance of behavior/lifestyle-mediated positive
caloric balance leading to adiposopathic endocrine and im-
mune responses, which in turn lead to metabolic disease.
Bariatric surgery’s effects on gut hormones (e.g., ghrelin)
Fig. 1 Obesity as a disease.
(Copyright American Society of
Bariatric Physicians 2013–2014
[41••])
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Table 2 Adiposopathy: Causality and illustrative anatomic, pathophysiologic, and clinical manifestations. [14••, 41••]
Causes of adiposopathy
• Positive caloric balance
• Sedentary lifestyle
• Genetic predisposition
• Environmental causes (e.g. certain medications, viral infections, pathologic gut microbiota signaling)
Anatomic manifestations of adiposopathy
• Adipocyte hypertrophy
• Increased visceral, pericardial, perivascular, and other periorgan adiposity
• Growth of adipose tissue beyond its vascular supply with ischemia, cellular death, apoptosis, and inflammation
• Increased number of adipose tissue immune cells
• “Ectopic fat deposition” in other body organs (liver, muscle, pericardial fat, perivascular fat, and possibly pancreas)
Pathophysiological manifestations of adiposopathy
• Impaired adipogenesis
• Pathological adipocyte organelle dysfunction (e.g. “stress” to adipocyte endoplasmic reticulum, mitochondria)
• Increased circulating free fatty acids (lipotoxicity)
• Pathogenic adipose tissue endocrine responses (e.g., increased leptin, increased tumor necrosis factor-alpha, decreased adiponectin, and increased
mineralocorticoids)
• Pathogenic adipose tissue immune responses (e.g., increased proinflammatory responses through increased tumor necrosis factor-alpha and decreased
anti-inflammatory responses through decreased adiponectin)
• Pathogenic interactions or pathogenic cross talk with other body organs (e.g., liver, muscle, central nervous system, and vasculature.)
Clinical manifestations of adiposopathy
• High glucose blood levels (prediabetes, type 2 diabetes mellitus)
• Insulin resistance
• High blood pressure
• Adiposopathic dyslipidemia
○ Increased triglyceride, triglyceride rich lipoprotein, and lipoprotein remnant levels
○ Decreased high density lipoprotein cholesterol levels
○ Increased atherogenic particle number (i.e. increased apolipoprotein B)




• Hypoandrogenemia in men
• Hyperandrogenemia in women






• Other inflammatory diseases (e.g. worsening depression, asthma, osteoarthritis)
Illustrative causes of metabolic diseases not due to adiposopathy
• Type 2 diabetes mellitus may be due to hemochromatosis, chronic pancreatitis, hypercortisolism, excessive growth hormone, genetic syndromes of
insulin resistance, and decreased pancreatic function (genetic syndromes, surgical excision, etc.).
•High blood pressure may be due to pheochromocytoma, primary hyperaldosteronism, hypercortisolism, hyperthyroidism, renal artery stenosis, various
kidney diseases, and familial or genetic syndromes.
• Dyslipidemia may be due to untreated hypothyroidism, poorly controlled diabetes mellitus, certain types of liver or kidney diseases, and genetic
dyslipidemias.
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favorably treat metabolic disease, and are effects perhaps
independent of fat weight loss [31]. However, although in-
triguing, it seems implausible to suggest that the very indica-
tion of bariatric surgery (which is to reduce the amount of
body fat in patients with obesity) is the mechanism least
applicable in improving metabolic diseases and reducing
CVD risk [45].
Perhaps the most compelling challenge to the central role
of adipocyte and adipose tissue as being the “primary cause”
of metabolic disease and increased CVD risk lies in cross talk
and interactions with other body organs. The brain is the
central location of behavior and hunger, and the hypothalamus
is a target for weight management pharmacotherapies [28••].
It is the “flexibility” of body organs such as the liver [46] and
muscle [47] to manage adiposopathic free fatty acid, endo-
crine, and immune onslaughts which largely determines the
degree of if and when an increase in the amount of body fat
ultimately contributes to metabolic diseases. So if disharmony
among multiple body organs ultimately determines whether
fat weight gain causes or worsens metabolic disease and CVD,
then how is the “primary cause” best assigned?
In the fourteenth century, William of Ockham established
Ockham’s razor: pluralitas non est ponenda sine necessitate
(“plurality should not be assumed unnecessarily”) [48]. By
emphasizing a principle of parsimony, economy, or succinct-
ness in problem-solving, Ockham’s razor postulates that
among competing theories with similar predictions, the sim-
pler one is better. Ockham’s razor does not require evidence
based on scientific results. It simply asserts that the explana-
tion requiring the fewest assumptions is best.
Adiposopathy is the simplest explanation as to why and
how increased body fat leads to metabolic disease and in-
creased CVD risk. Scientific organizations have arguably
conceded this point by designating adipose tissue as the only
organ criterion (central obesity) which helps define metabolic
syndrome (Table 1). The final main caveat is acknowledging
not all metabolic diseases are due to adiposopathy [14••]
(Table 2).
With this remaining caveat acknowledged, if Ockham’s
razor is applied to clinical medicine (along with the patient-
centered provision that reversibility is preferred over irrevers-
ibility when assigning causation), then a logical conclusion
might be: “When multiple abnormalities promote an adverse
health outcome, it is the defect most directly, simply, and
reversibly associated with promoting a disease, and the defect
most beneficial when corrected, which is best labeled the
‘primary cause’.” By use of this definition, among patients
with overweight and/or obesity, adiposopathy is not just the
primary cause, but is the commonest cause of type 2 diabetes
mellitus, high blood pressure, dyslipidemia, and increased
CVD risk.
Few challenge cardiomyopathy as a primary diagnosis for
patients with congestive heart failure. This is even when its
pathogenic potential may be dependent on genetics (hypertro-
phic cardiomyopathy), nutritional anomalies (alcohol, and
deficiencies of thiamin, selenium, calcium, and magnesium),
medications (cocaine, tricyclic antidepressants, etc.), ischemia
(atherosclerosis), infections (adenovirus, staphylococcus,
etc.), or toxins (cobalt). Cardiomyopathy is a primary diagno-
sis, even when largely promoted by diseases of other body
organs diseases such as the vasculature (e.g., high blood
pressure), lung (cor pulmonale), kidney (renal failure), and
thyroid, and more widespread disorders such as hemochroma-
tosis, sarcoidosis, amyloidosis, and connective tissue disease.
Similarly, adiposopathy is a primary diagnosis for patients
with various metabolic diseases (Table 2) that occur or worsen
with increased adiposity. This is even when its pathogenic
potential may be dependent on genetics, nutritional anomalies
(positive caloric balance), medications (sulfonylureas, tricy-
clic antidepressants, etc.), ischemia (adipocyte and adipose
tissue hypoxia), viral infections (adenovirus, gut microbiota,
etc.), and toxins. Adiposopathy is a primary diagnosis, even
when disorders of other body organs such as the liver, muscle,
and brain are operative as well.
Adiposopathy and the Obesity Paradox
The “obesity paradox” describes seemingly contrary relation-
ships between body fat and health/ill-health. These apparent
paradoxical relationships between body fat and health/ill-
health are made less paradoxical after identifying
adiposopathy and sick fat as the “primary cause” of
adiposity-related metabolic disease and increased CVD risk.
The anatomic obesity paradox suggests that abdominal adi-
pose tissue distribution is paradoxically more pathologic than
the peripheral adipose tissue distribution. If during positive
caloric balance, peripheral subcutaneous adipose tissue (SAT)
is able to undergo unfettered adipocyte proliferation and differ-
entiation, then this may mitigate energy overflow to other fat
depots [49]. Conversely, if SAT is not able to adequately prolif-
erate and differentiate during positive caloric balance (a type of
“acquired lipodystrophy”) [50], then the energy overflow (i.e.,
via increased circulating free fatty acids) may promote fat accu-
mulation in other fat depots [e.g., visceral adipose tissue (VAT),
pericardial fat, and perivascular fat]. Increased circulating free
fatty acids may also infiltrate, and be “lipotoxic” to nonadipose
tissue such as the liver, muscle, pancreas, heart, and kidney [51,
52]. In short, CVD may result directly from local-fat-depot-
mediated adiposopathic and atherogenic processes [53–55] or
indirectly through onset or worsening of metabolic diseases,
many beingmajor CVD risk factors [6, 14••, 27•, 28••, 29, 56••].
The physiologic obesity paradox applies when fat mass
accumulation has seemingly paradoxical relationships to met-
abolic disease. Benign multiple symmetrical lipomatosis is
manifested by increased accumulation of SAT, via increased
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proliferation of smaller, more functional adipocytes and in-
creased secretion of anti-inflammatory adipokines such as
adiponectin. Despite an increased amount body fat in these
regions, patients with benign multiple symmetrical
lipomatosis do not have an increased risk of hyperglycemia
or dyslipidemia [57]. Conversely, inherited lipodystrophy is
manifested by variable lack of body fat with low adiponectin
levels. Because fat storage is limited, increased circulating
free fatty acid levels promote lipotoxicity towards nonadipose
body organs [58]. Despite having less body fat, patients with
inherited lipodystrophy often have metabolic abnormalities
such as hypertriglyceridemia and hyperglycemia [20, 59].
When the amount of fat is the only consideration, these
genetic conditions may appear paradoxical. When considered
within the context of fat function/dysfunction, then they are
less paradoxical. Patients described as “metabolically healthy,
but obese,” and “metabolically obese, but normal
weight” [20] seem to identify physiologic obesity para-
doxes. Although “metabolically healthy, but obese” pa-
tients may not actually be so “healthy” [60, 61•], they
do suggest that when unfettered peripheral SAT accu-
mulation helps mitigate adipocyte and adipose tissue
pathogenic endocrine and immune responses, then this
reduces the potential to cause metabolic disease [62].
Conversely, when positive caloric balance occurs in
those with more limited proliferation and differentiation
of peripheral SAT (“metabolically obese, but normal
weight”), then energy overflow to other fat depots may
promote adiposopathic endocrine and immune responses,
contribute to metabolic disease, and increase CVD risk
[20, 63].
The demographic obesity paradox includes apparent gen-
der and ethnic paradoxes. Since the 1940s [13], women have
been described to have a “paradoxical” age-adjusted reduced
risk of CVD [64], compared with men, substantially because
of increased proliferation and differentiation of fat cells in the
less pathogenic SAT regions (“pear distribution”). This con-
trasts with the more limited proliferation and differentiation of
fat cells in the SATof men, resulting in more pathogenic VAT
accumulation (“apple distribution”) [65]. Regarding races and
ethnicities, Asians typically have fewer adipocytes, increased
adipocyte size, increased amount of visceral fat, increased
circulating free fatty acid levels, elevated leptin levels, in-
creased levels of proinflammatory factors (e.g., C-reactive
protein), and decreased levels of anti-inflammatory factors
(e.g., adiponectin) [14••]. These classic adiposopathic findings
(Table 2) help account for the onset or worsening of metabolic
abnormalities and increased CVD risk among Asians, even
when they are not markedly overweight. It also helps explain
why compared with people of European descent, Asians have
different waist circumference cutoff points for defining meta-
bolic syndrome [19], and may require different BMI cutoff
points for defining overweight/obesity [66].
The therapeutic obesity paradox describes the seemingly
paradoxical effects of therapeutic interventions on body fat
and metabolic disease.When lipoatrophic mice (with virtually
no white adipose tissue) undergo transplant of functional fat,
hyperglycemia, hyperinsulinemia, and muscle insulin sensi-
tivity all improve [67]. Peroxisome-proliferator-activated
receptor γ agonists increase the proliferation and differentia-
tion of adipocytes, improve the SAT to VAT ratio, lower
glucose levels, may improve lipid levels, and may reduce
CVD risk [68]. These examples illustrate how adding func-
tional fat can improve metabolic diseases that, paradoxically,
are usually due to having too much body fat. Human immu-
nodeficiency virus (HIV) patients treated with antiretroviral
agents may develop loss of functional SAT relative to VAT
(i.e., HIV lipodystrophy) [69]. Despite weight loss, patients
“paradoxically” experience onset or worsening of metabolic
disease [58]. Finally, if prognoses are based on fat function
rather than fat mass, liposuction of functional SATwould not
be expected to improve, and in fact does not improve, CVD
risk factors such as hyperglycemia, high blood pressure, and
dyslipidemia [70].
The CVD event and/or intervention obesity paradox refers
to more favorable outcomes observed among patients with
overweight or obesity who experience a CVD event, or un-
dergo a cardiovascular procedure, compared with thinner
individuals. This may be especially so if the comparator
individuals are thin because of severe illnesses (e.g., chronic
heart or lung disease, cancer), or because the thinner
individuals smoke cigarettes, which would not only reduce
body weight, but would also increase CVD risk [71, 72].
Men who are overweight or obese may have reduced
mortality only if they are physically fit [73, 74]. Patients
with chronic heart failure seem to have no mortality benefit if
they have type 2 diabetes mellitus [75]. In fact, all nonsmok-
ing type 2 diabetes mellitus patients with overweight and/or
obesity may have increased mortality compared with normal-
weight counterparts, with little evidence of an obesity paradox
[76].
Confounders may be operative as well. An increase in the
amount of body fat may heighten awareness of potential CVD
risk factors when a patient presents with overweight or obesi-
ty. This may increase global medical care compared with that
for those not thought to be at increased CVD risk. Addition-
ally, many patients with overweight or obesity are treated with
metabolic drug treatments (e.g., statins, antihypertensive
agents, anti-thrombotic agents), which are proven to reduce
CVD morbidity and mortality, and represent treatments pos-
sibly not affordable to those who are not overweight or obese
[14••].
Also, although the adiposopathic mechanisms accounting
for CVD in patients with overweight or obesity are more
prevalent, the pathologic mechanisms accounting for CVD
in thinner patients may bemore pathologic. Most patients who
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experience a CVD event have modestly elevated choles-
terol levels. Conversely, genetic dyslipidemias, such as
familial hypercholesterolemia, result in profound in-
creases in cholesterol levels, irrespective of whether
the patient has an increased amount of body fat. None-
theless, although less common, many adipose tissue
independent genetic dyslipidemias are much more ag-
gressive in promoting CVD [14••]. Similarly, the CVD
of thinner patients may reflect more aggressive genetic/
environmentally mediated diseases, which although less
prevalent than adiposopathy, may have increased CVD
morbidity and mortality.
Finally, adipose tissue is an abundant source of mes-
enchymal stem cells, which may provide enhanced car-
diovascular autorepair [14••]. Adipose-tissue-derived
stem cells have the potential to develop into adipocytes,
blood vessel cells, or cardiomyocytes [14••]. After an
acute CVD event or cardiovascular procedure, circulat-
ing stem/progenitor cells derived from adipose tissue
may migrate to the disrupted or injured myocardial or
vascular site. Individuals with overweight or obesity
have greater mobilization of progenitor cells into the
circulation compared with thinner individuals [77].
Thus, after an individual has experienced a CVD event
or undergone a cardiovascular procedure, the greater
availability of progenitor cells may afford greater car-
diovascular self-repair and improved CVD outcomes
[78, 79].
The obesity treatment paradox is the apparent lack of
improved CVD outcomes with weight reduction in pa-
tients who are overweight or obese. If an increase in the
amount of body fat is the “primary cause” of
adiposopathic endocrine and immune responses leading
to most cases of metabolic diseases and increased CVD
risk, then weight reduction would be expected to im-
prove metabolic disease and reduce CVD risk. The
Look AHEAD (Action for Health in Diabetes) study
was an 8-year study that compared an education-only
group with an intensive therapy group in patients with
overweight or obesity and type 2 diabetes mellitus [80].
Patients in the intensive therapy group lost more weight,
had lower hemoglobin A1c levels, and required fewer
medications. However, the incidence of CVD was not
reduced despite weight loss, increased exercise, and
improvement in metabolic diseases [81]. This suggests
intensive behavioral and lifestyle weight loss interven-
tions are effective in treating adiposopathy and improv-
ing metabolic parameters in overweight and/or obese
patients with metabolic disease. But with specific regard
to reduce the risk of CVD, the best available evidence
suggests that relative to behavior therapy and lifestyle
changes, treatment might best be directed towards
treating the adverse consequences of long-standing
adiposopathy. This may include use of statins, antihy-
pertensive agents, antithrombotic agents, etc. A notable
exception is bariatric surgery. The degree of weight loss
achieved with bariatric surgery, in addition to its other
favorable hormonal/inflammatory effects, is reported to
improve metabolic disease among patients who are
overweight or obese, and may also decrease CVD mor-
bidity and mortality [82]. This supports “sick fat” as a
surgical disease [31].
Conclusion
Adiposopathy is defined as pathologic adipose tissue
anatomic/functional disturbances promoted by positive
caloric balance in genetically and environmentally sus-
ceptible individuals which results in adverse endocrine
and immune responses that both directly and indirectly
contribute to metabolic disease and increased CVD risk.
A clinical application of Ockham’s razor suggests
adiposopathy as the “primary cause” of most cases of
metabolic diseases such as high glucose levels, high
blood pressure, and dyslipidemia, as well as most cases
of CVD. Perhaps the most important “paradoxical” find-
ing relative to obesity is determining when adiposopathy
is best treated. Weight management interventions in
patients with overweight/obesity and metabolic disease
generally improve metabolic parameters. However, with
the possible exception of bariatric surgery, weight man-
agement interventions (e.g., behavior and lifestyle rec-
ommendations) alone among patients with advanced
metabolic disease may not reduce CVD risk. Some
metabolic disease guidelines suggest the most aggressive
treatments of metabolic disorders are reserved for those
with the most advanced disease. For example, lipid
guidelines suggest patients with CVD should receive
the most aggressive lipid therapies [83–85]. However,
for adiposopathy, the greatest CVD benefit of weight
management via behavior and lifestyle interventions
may be to prevent metabolic diseases and avoid CVD
risk factors in the first place. That is because those who
never develop metabolic disease and CVD risk factors
would be expected to reduce their risk of CVD. Con-
versely, if therapy is delayed until patients with over-
weight and/or obesity develop metabolic diseases and
CVD risk factors and experience CVD events, then this
would increase their CVD risk, which at that stage, may
not be as responsive to nutritional and physical activity
interventions. To some, placing a higher priority on
obesity prevention relative to obesity treatment may
seem paradoxical. But Benjamin Franklin (1706–1790)
once said: “An ounce of prevention is worth a pound of
409, Page 8 of 11 Curr Atheroscler Rep (2014) 16:409
cure.” That prevention might be considered paradoxical
is perhaps the greatest obesity paradox of all.
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